Get the Stockscreener App
4.78
6.94%
0.31
Pre-market:
4.87
0.09
+1.88%
Cingulate Inc stock is traded at $4.78, with a volume of 863.00K.
It is up +6.94% in the last 24 hours and down -12.61% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
See More
Previous Close:
$4.47
Open:
$4.45
24h Volume:
863.00K
Relative Volume:
1.67
Market Cap:
$63.46M
Revenue:
-
Net Income/Loss:
$-27.71M
P/E Ratio:
-1.1217
EPS:
-4.2615
Net Cash Flow:
$-19.77M
1W Performance:
+8.88%
1M Performance:
-12.61%
6M Performance:
+30.25%
1Y Performance:
+30.60%
1-Day Range:
$4.42
$5.15
1-Week Range:
$4.343
$5.15
52-Week Range:
$3.20
$11.89
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.78 | 59.34M | 0 | -27.71M | -19.77M | -4.2615 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
H.C. Wainwright Maintains Cingulate(CING.US) With Buy Rating, Maintains Target Price $20 - Moomoo
CING Reiterated by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus
Cingulate stock reaffirmed at Buy by H.C. Wainwright ahead of FDA decision - Investing.com UK
CING Stock Price, Quote & Chart | CINGULATE INC (NASDAQ:CING) - ChartMill
Cingulate Reshapes Board Structure and Leadership Roles - The Globe and Mail
Roth MKM Maintains Cingulate(CING.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Cingulate to reduce board size as directors opt not to seek re-election - Investing.com
Jeff Hargroves reappointed to Cingulate board as Class II; Jeff Ervin and Jay Roberts to not seek re-election - TradingView
Board reshuffle at Cingulate (NASDAQ: CING) as directors plan exit - Stock Titan
Cingulate Inc. (CING) schedules virtual annual meeting, equity plan vote - Stock Titan
CING: Building its cash position - MSN
Cingulate Inc.Warrants (NQ: CINGW - FinancialContent
Maxim Group Maintains Cingulate(CING.US) With Buy Rating, Maintains Target Price $8 - Moomoo
CING Should I Buy - Intellectia AI
Cingulate Inc. 2026 Q1 10-Q Filing: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Cingulate Reports Q1 2026 Financial Results, Grows Cash to $25.9M, Advances CTx-1301 ADHD NDA Toward FDA Decision - Minichart
Cingulate reports Q1 loss, raises cash runway into 2027 By Investing.com - Investing.com Nigeria
Cingulate reports Q1 loss, raises cash runway into 2027 - Investing.com India
Cingulate Inc. 1Q 2026: Revenue $0 Net loss $(9.31M) — 10-Q Summary - TradingView
Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cingulate (NASDAQ: CING) widens Q1 2026 loss while boosting cash for CTx-1301 launch prep - Stock Titan
Cingulate Reports Q1 2026: Cash Rises to $25.9M, Net Loss $9.3M - TradingView
Cash builds as Cingulate (NASDAQ: CING) readies CTx-1301 ahead of FDA date - Stock Titan
Press Release: Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for Lead ADHD Asset CTx-1301 - Moomoo
TradingKey - TradingKey
Cingulate (CING) EVP receives 3,422-share stock option award - Stock Titan
Why did Cingulate stock skyrocket today? - MSN
Cingulate (CING) to Release Quarterly Earnings on Thursday - MarketBeat
At least five PDUFA dates on FDA’s May docket - BioCentury
FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate - BioSpace
Cingulate Inc. (NASDAQ:CING) Short Interest Up 31.7% in April - MarketBeat
What's going on with Cingulate stock today? - MSN
Cingulate Inc. (NASDAQ: CING) registers 4.21M common shares for resale - Stock Titan
[EFFECT] Cingulate Inc. SEC Filing - Stock Titan
Here is Why Cingulate (CING) is One of the Best NASDAQ Growth Stocks to Buy and Hold Forever - Insider Monkey
CING Options Volatility — NASDAQ:CING - TradingView
CING Options Chain — NASDAQ:CING - TradingView
Should I buy or sell Cingulate (CING) stock today | Q4 2025: Earnings Fall ShortShared Momentum Picks - Xã Châu Thành
CING (Cingulate Inc.) shares fall 2.8% after Q4 2025 EPS misses analyst estimates by a wide margin.Dividend Report - Xã Châu Thành
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
CING SEC FilingsCingulate Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):